Late-life Depression
Conditions
Interventions
Trial Group:Ranscutaneous Auricular Vagus Nerve Stimulation
Sponsors
Chongqing Mental Health Center
Eligibility
Sex/Gender
All
Age
60 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 60 years, right-handed, regardless of gender; 2. Meeting the diagnostic criteria for depressive disorders as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); 3. No antidepressant treatment during the current episode, or antidepressant use for less than 7 days in the recent 14 days; 4. A score of >= 17 points on the 17-item Hamilton Depression Rating Scale (HAMD-17) (indicating moderate depression or above); 5. A score below one standard deviation or more compared with the normal control group in at least one of the Trail Making Test Part A (TMT-A) and Trail Making Test Part B (TMT-B); 6. A score of > 20 points on the Mini-Mental State Examination (MMSE) for patients with primary school education, and > 24 points on the MMSE for patients with junior high school education or above; 7. Having an education level of primary school or above, and being able to understand the content of the scales and tests; 8. Providing written informed consent by the patients themselves.
Exclusion criteria
Exclusion criteria: 1. A history of or current diagnosis of cranial diseases, brain injury, epileptic seizures, or other neurological disorders; 2. A history of or current diagnosis of severe or unstable diseases of the cardiovascular, respiratory, immune, or other systems; patients with critical conditions or organ failure of major importance; 3. A history of or current diagnosis of the following psychiatric disorders as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5): organic mental disorders, Alzheimer’s disease, secondary dementia due to other causes, schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorder, unspecified mental disorders, alcohol (or drug) dependence or abuse, and personality disorders; 4. Patients with a high risk of suicide; 5. Presence of contraindications to transcutaneous auricular vagus nerve stimulation (taVNS), such as severe allergy to electrode patches, local skin damage or inflammation, and hyperalgesia in the stimulation area; 6. Subjects;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TMT-A/B score;HAMD-17 score;Color word Stroop task; | — |
Secondary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment Scale (MoCA;Functional near - infrared spectroscopy; | — |
Countries
China
Contacts
Public ContactLiu Shengyan
Chongqing Mental Health Center
Outcome results
None listed